Credit Suisse’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Credit Suisse’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-10,221	Closed	-$176K	–	4294
2019 Q1	$176K	Buy	+10,221	New	+$186K	﹤0.01%	3788
2017 Q3	–	Sell	-23,012	Closed	-$201K	–	4293
2017 Q2	$201K	Buy	+23,012	New	+$203K	﹤0.01%	3619
2016 Q3	–	Sell	-10,311	Closed	-$123K	–	4326
2016 Q2	$123K	Buy	+10,311	New	+$166K	﹤0.01%	4024
2015 Q3	–	Sell	-7,794	Closed	-$293K	–	4572
2015 Q2	$293K	Sell	7,794 -8,922	-53%	-$288K	﹤0.01%	4028
2015 Q1	$525K	Buy	+16,716	New	+$452K	﹤0.01%	3514

Other funds holding CBMG

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $397M AUM 63.96% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Credit Suisse's CBMG Position: Q2 2019 in Review

Credit Suisse sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2019, closing a stake of 10,221 shares — an estimated $176K sold.

Credit Suisse first reported a position in CBMG in Q1 2015 and held it in 5 quarters. The position peaked at $525K in Q1 2015. 40 funds tracked by Wall St. Rank hold CBMG as of Q2 2019.

Credit Suisse reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2019 after selling out during the quarter.
Credit Suisse sold 10,221 Cellular Biomedicine Group, Inc. shares in Q2 2019, an estimated $176K.
Credit Suisse first reported a position in Cellular Biomedicine Group, Inc. in Q1 2015 and held it in 5 quarters.
Credit Suisse's Cellular Biomedicine Group, Inc. position peaked at $525K in Q1 2015.
40 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2019.

Based on Credit Suisse's 13F filing for Q2 2019, filed 14 Aug 2019.